Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LMY-920 · 1 trial · 1 indication
The rate of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (National Cancer Institute) and rate of dose limiting toxicities after treatment with autologous BAFF CAR-T cells in adults with refractory SLE
A dose of autologous BAFF CAR-T cells in adults with refractory SLE less than or equal to that at which less than or equal to 1/6 patients experience dose limiting toxicities.
| Arm | Type | Description |
|---|---|---|
| BAFF CAR T | EXPERIMENTAL | Autologous BAFF CAR T Therapy |
| Name | Type | Description |
|---|---|---|
| LMY-920 | BIOLOGICAL | CAR T Therapy |
Inclusion Criteria: * Age 18-69 years * Confirmed Systemic Lupus Erythematosus (SLE) as per Systemic Lupus International Collaborating Clinics (SLICC) 2012 Criteria with one or more of the following: a. Active disease despite use of standard therapy (i) and one or more additional therapies (ii)....
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
LMY-920 is an investigational monoclonal antibody being developed for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in a clinical trial enrolling adult patients with SLE.
LMY-920 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting a Phase 1 clinical trial of this investigational therapy for Systemic Lupus Erythematosus.
LMY-920 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants with Systemic Lupus Erythematosus.
LMY-920 is being studied in a Phase 1 clinical trial registered as NCT06340750, titled 'BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus'. This single-center, uncontrolled trial is recruiting 18 adult patients in the United States and is not yet completed.
Yes, LMY-920 is also referred to as BAFF CAR-T cells in the clinical trial context. The Phase 1 study NCT06340750 explicitly names 'BAFF CAR-T Cells (LMY-920)' as the investigational therapy, indicating that LMY-920 is a CAR-T cell product targeting BAFF for the treatment of Systemic Lupus Erythematosus.